Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 589 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with... December 12, 2024 Urine test for bladder cancer being developed July 2, 2021 ScottishPower supports vital research into air pollution and cancer November 24, 2022 Mom Goes From Worried To Mortified After Finding Dark Brown Spot... June 4, 2019 Load more HOT NEWS EMA Recommends Extension of Indications for Olaparib A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target... Study Shows That Fast-Mimicking Diets Are Safe and Effective for Patients... Addressing Common Sexual Health Concerns During Cancer Survivorship: An Expert Perspective
